Glaukos Corporation to Release First Quarter 2019 Financial Results after Market Close on May 8

Conference Call and Webcast Scheduled for 1:30 p.m. PDT

SAN CLEMENTE, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and
pharmaceutical company focused on the development and commercialization
of novel surgical devices and sustained pharmaceutical therapies
designed to transform the treatment of glaucoma, plans to release first
quarter 2019 financial results after the market close on Wednesday, May
8, 2019. The company’s management will discuss the results during a
conference call and simultaneous webcast at 1:30 p.m. PDT (4:30 p.m.
EDT) on May 8, 2019.

A link to the live webcast will be available on the company’s website at http://investors.glaukos.com.
To participate in the conference call, please dial 833-231-8262 (U.S.)
or 647-689-4107 (International) and enter Conference ID 9977628. A
replay will be archived on the company’s website following completion of
the call.

About Glaukos

Glaukos (www.glaukos.com)
is an ophthalmic medical technology and pharmaceutical company focused
on the development and commercialization of novel surgical devices and
sustained pharmaceutical therapies designed to transform the treatment
of glaucoma, one of the world’s leading causes of blindness. The company
pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the
traditional glaucoma treatment and management paradigm. Glaukos launched
the iStent^®, its first MIGS device, in the United
States in July 2012 and launched its next-generation iStent inject^®
device in the United States in September 2018. Glaukos is leveraging its
platform technology to build a comprehensive and proprietary portfolio
of micro-scale injectable therapies designed to address the complete
range of glaucoma disease states and progression. The company believes
the iStent inject, measuring 0.23 mm wide and 0.36 mm long, is
the smallest medical device ever approved by the FDA.

Contacts

Chris Lewis
Director, Investor Relations, Corporate Strategy &
Development
(949) 481-0510
[email protected]